Novo Nordisk’s CagriSema Delivers Strong HbA1c and Weight Loss Results in Phase 3 REIMAGINE Trials
Plainsboro, New Jersey and Bagsværd, Denmark, June 7, 2026 Novo Nordisk has unveiled compelling Phase 3 clinical data for...
Novo Nordisk
Advertisement
Novo Nordisk Reports Strong Phase 2 Zenagamtide Data
PLAINSBORO, N.J. and BAGSVÆRD, Denmark, June 6, 2026 Novo Nordisk has announced positive results from a Phase 2 clinical...
Novo Nordisk Launches Wegovy Pill in UAE Market
BAGSVÆRD, Denmark, June 3, 2026 Novo Nordisk has announced the launch of Wegovy® pill (semaglutide tablets) in the United...
Novo Nordisk’s Wegovy 7.2 mg Wins CHMP Support
BAGSVÆRD, Denmark, May 22, 2026 Novo Nordisk announced that the European Medicines Agency’s Committee for Medicinal Products for Human...
Novo Nordisk Expands Wegovy Leadership at ECO 2026
BAGSVAERD, Denmark, May 12, 2026 Novo Nordisk announced new clinical findings at the 2026 European Congress on Obesity (ECO...
Advertisements
Novo Nordisk Reports 28% Weight Loss With Higher-Dose Wegovy
Bagsværd, Denmark, May 12, 2026 Novo Nordisk presented new analyses from its pivotal STEP UP clinical trial at the...
Novo Nordisk Reports Strong Phase 3 Results for Denecimig in Hemophilia A
PLAINSBORO, N.J. & BAGSVAERD, Denmark, April 29, 2026 Novo Nordisk has announced that its investigational therapy denecimig (Mim8) significantly...
Novo Nordisk Oral Semaglutide Shows Pediatric Breakthrough
Bagsværd, Denmark – April 23, 2026 In a major advancement for pediatric diabetes care, Novo Nordisk announced positive Phase...
Novo Nordisk Reports Etavopivat Phase 3 Breakthrough
Bagsværd, Denmark, April 20, 2026 Novo Nordisk has announced breakthrough Phase 3 clinical trial results for etavopivat, a first-in-class...
Novo Nordisk Secures EMA Approval for Wegovy Delivery Flexibility
Bagsværd, Denmark | April 9, 2026 Novo Nordisk has announced that the European Medicines Agency (EMA) has approved an...
Advertisement
